Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.64 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.64 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009041 | 1.00 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30481109 | 1.00 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2009040 | 1.00 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3739643 | 0.85 | CYP1A1 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3739640 | 0.85 | CYP1A1 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3638744 | 0.85 | HPGD (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3638747 | 0.85 | HPGD (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11747282 | 0.85 | GRIN2D (0.73) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3717558 | 0.84 | LMNA (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3717557 | 0.84 | LMNA (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998005630-A1 | PROCESS FOR THE PREPARATION OF ORGANIC NITRILES | ALLIEDSIGNAL INC. (US) | 1998-02-12 | — | — | WO | claimed |
| CN-113861069-A | Preparation method of nitrile compound | 陕西国际商贸学院 | 2021-12-31 | — | — | CN | disclosed |
| CN-111244547-B | Electrolyte containing aromatic oxime additive and preparation method and application thereof | 四川虹微技术有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-111244547-A | Electrolyte containing aromatic oxime additive and preparation method and application thereof | 四川虹微技术有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| WO-2008106139-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007025307-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-1998005630-A1 | PROCESS FOR THE PREPARATION OF ORGANIC NITRILES | ALLIEDSIGNAL INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| US-4581365-A | Trichloroacryloyl oxime fungicides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | GRIN2D 4664/4885GRIN3B 3788/4885GRIN1 3237/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | GRIN2D 4664/4885GRIN3B 3788/4885GRIN1 3237/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | GRIN2D 4559/4885GRIN3B 3675/4885GRIN1 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.